“We are working diligently to collect and analyze the definitive data that we need to complete our PMA application seeking approval from the FDA for the VenoValve and we look forward to releasing that data to the public,” commented Robert Berman, CEO of enVVeno Medical (NVNO). “We are getting closer to seeing the results from all of the time and effort we have spent over the past 6 years, and it is an exciting time for everybody affiliated with our Company.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVNO:
- enVVeno Medical initiates six-month pre-clinical GLP study of enVVe
- enVVeno Medical 4.3M share Spot Secondary priced at $3.50
- enVVeno Medical offers to sell common stock
- enVVeno Medical appoints Sandy Prietto as VP, marketing
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
